- HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME
-
The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosis. Formula (I) i
- -
-
-
- HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF
-
The present disclosure provides heteroaryl compounds of formulas (I), (Ia) and (Ib), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosi
- -
-
-
- FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE
-
The invention relates to compounds of formula (I) for the regulation of phosphoinositides 3-kinases activity and related diseases.
- -
-
Page/Page column 105
(2010/09/18)
-
- Inhibitors of PI3 kinase
-
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof, that inhibit phosphoinositide 3-kinase; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds.
- -
-
Page/Page column 33
(2009/07/10)
-
- BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
-
Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.
- -
-
Page/Page column 74
(2009/03/07)
-
- PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE
-
Phosphatidylinositol (PI) 3 kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceuticall
- -
-
Page/Page column 65
(2010/11/28)
-